121 related articles for article (PubMed ID: 37988194)
1. Alendronate Pt
Sun K; Yuan L; Chen S; Sun Y; Wei D
Adv Healthc Mater; 2024 Mar; 13(7):e2302746. PubMed ID: 37988194
[TBL] [Abstract][Full Text] [Related]
2. Dual targeting curcumin loaded alendronate-hyaluronan- octadecanoic acid micelles for improving osteosarcoma therapy.
Xi Y; Jiang T; Yu Y; Yu J; Xue M; Xu N; Wen J; Wang W; He H; Shen Y; Chen D; Ye X; Webster TJ
Int J Nanomedicine; 2019; 14():6425-6437. PubMed ID: 31496695
[TBL] [Abstract][Full Text] [Related]
3. Nano-assembly of ursolic acid with platinum prodrug overcomes multiple deactivation pathways in platinum-resistant ovarian cancer.
Wang Y; Luo Z; Zhou D; Wang X; Chen J; Gong S; Yu Z
Biomater Sci; 2021 Jun; 9(11):4110-4119. PubMed ID: 33949442
[TBL] [Abstract][Full Text] [Related]
4. Nuclear-Targeting Lipid Pt
Wei D; Fan J; Yan J; Liu C; Cao J; Xu C; Sun Y; Xiao H
J Am Chem Soc; 2024 Jan; 146(1):1185-1195. PubMed ID: 38148611
[TBL] [Abstract][Full Text] [Related]
5. Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy.
Zhong J; Wen W; Wang J; Zhang M; Jia Y; Ma X; Su YX; Wang Y; Lan X
Pharm Res; 2023 Jan; 40(1):231-243. PubMed ID: 36380167
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate-functionalized coordination polymer nanoparticles for the treatment of bone metastatic breast cancer.
He Y; Huang Y; Huang Z; Jiang Y; Sun X; Shen Y; Chu W; Zhao C
J Control Release; 2017 Oct; 264():76-88. PubMed ID: 28842315
[TBL] [Abstract][Full Text] [Related]
7. Development of Novel Pt(IV)-Carbohydrate Derivatives as Targeted Anticancer Agents against Osteosarcoma.
Moynihan E; Panseri S; Bassi G; Rossi A; Campodoni E; Dempsey E; Montesi M; Velasco-Torrijos T; Montagner D
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047001
[TBL] [Abstract][Full Text] [Related]
8. Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy.
Yang GG; Pan ZY; Zhang DY; Cao Q; Ji LN; Mao ZW
ACS Appl Mater Interfaces; 2020 Sep; 12(39):43444-43455. PubMed ID: 32883070
[TBL] [Abstract][Full Text] [Related]
9. Reduction of Platinum(IV) Prodrug Hemoglobin Nanoparticles with Deeply Penetrating Ultrasound Radiation for Tumor-Targeted Therapeutically Enhanced Anticancer Therapy.
Liang G; Sadhukhan T; Banerjee S; Tang D; Zhang H; Cui M; Montesdeoca N; Karges J; Xiao H
Angew Chem Int Ed Engl; 2023 May; 62(22):e202301074. PubMed ID: 36961095
[TBL] [Abstract][Full Text] [Related]
10. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
Datta P; Bang S; Yue Z; Beach T; Stilgenbauer M; Wang H; Bowers DJ; Kurokawa M; Xiao H; Zheng YR
Dalton Trans; 2020 Jun; 49(24):8107-8113. PubMed ID: 32490446
[TBL] [Abstract][Full Text] [Related]
11. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles.
Dhar S; Gu FX; Langer R; Farokhzad OC; Lippard SJ
Proc Natl Acad Sci U S A; 2008 Nov; 105(45):17356-61. PubMed ID: 18978032
[TBL] [Abstract][Full Text] [Related]
12. Low molecular weight heparin modified bone targeting liposomes for orthotopic osteosarcoma and breast cancer bone metastatic tumors.
Wu H; Luo Y; Xu D; Ke X; Ci T
Int J Biol Macromol; 2020 Dec; 164():2583-2597. PubMed ID: 32795579
[TBL] [Abstract][Full Text] [Related]
13. A red-light activatable and mitochondrion-targeting Pt
Li Y; Wang Z; Qi Y; Tang Z; Li X; Huang Y
Chem Commun (Camb); 2022 Jul; 58(60):8404-8407. PubMed ID: 35796077
[TBL] [Abstract][Full Text] [Related]
14. Imidazole modified Pt(iv) prodrug-loaded multi-stage pH responsive nanoparticles to overcome cisplatin resistance.
Kang X; Wang Y; Chen Z; Wu Y; Chen H; Yang X; Yu C
Chem Commun (Camb); 2020 Sep; 56(76):11271-11274. PubMed ID: 32830841
[TBL] [Abstract][Full Text] [Related]
15. An upconversion nanoplatform for simultaneous photodynamic therapy and Pt chemotherapy to combat cisplatin resistance.
Ai F; Sun T; Xu Z; Wang Z; Kong W; To MW; Wang F; Zhu G
Dalton Trans; 2016 Aug; 45(33):13052-60. PubMed ID: 27430044
[TBL] [Abstract][Full Text] [Related]
16. The novel platinum(IV) prodrug with self-assembly property and structure-transformable character against triple-negative breast cancer.
Yang C; Tu K; Gao H; Zhang L; Sun Y; Yang T; Kong L; Ouyang D; Zhang Z
Biomaterials; 2020 Feb; 232():119751. PubMed ID: 31918218
[TBL] [Abstract][Full Text] [Related]
17. Fabricating nanoparticles co-loaded with survivin siRNA and Pt(IV) prodrug for the treatment of platinum-resistant lung cancer.
Ma S; Li X; Ran M; Ji M; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X
Int J Pharm; 2021 May; 601():120577. PubMed ID: 33839227
[TBL] [Abstract][Full Text] [Related]
18. Reduction-responsive sulfur dioxide polymer prodrug nanoparticles loaded with irinotecan for combination osteosarcoma therapy.
Li Y; Qu J; Zhang P; Zhang Z
Nanotechnology; 2020 Nov; 31(45):455101. PubMed ID: 32688350
[TBL] [Abstract][Full Text] [Related]
19. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
[TBL] [Abstract][Full Text] [Related]
20. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo.
Dhar S; Kolishetti N; Lippard SJ; Farokhzad OC
Proc Natl Acad Sci U S A; 2011 Feb; 108(5):1850-5. PubMed ID: 21233423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
